Slides
Page 1
1 Creating anti-infective opportunities Webcast presentation | August 18, 2026 Shaping the Future of Infectious Diseases Half-year results 2026
Page 2
2 Creating anti-infective opportunities Chief Executive Officer David Veitch Introduction
Page 3
3 Creating anti-infective opportunities Disclaimer This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 4
4 Creating anti-infective opportunities Half-year 2026 – Highlights Delivering strong financial results and positioning the company for future success *MAT Q1/2025 vs. Q1/2026; MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Fosmanogepix: phase 3 on track; BARDA funding tranche secured through enrollment milestone achievement BAL2420: initiated first- in-human phase 1 study with novel antibiotic PORTFOLIO Total revenue up 14% y-o-y to CHF 119 million Awarded USD 61 million of non-dilutive funding from BARDA and CARB-X Net cash position doubled y-o-y to CHF 105 million FINANCIALS Cresemba global in- market sales increased by 27% to USD 782 million* Operating profit increased by 32% y-o-y to CHF 32 million Prokaryotics: entered collaboration to develop a novel broad-spectrum antifungal
Page 5
5 Creating anti-infective opportunities Assets Preclinical Phase 1 Phase 2 Phase 3 Market COMMERCIAL Cresemba® isavuconazole Invasive mold infections¹ Zevtera® ceftobiprole HABP, CABP, SAB, ABSSSI¹ PHASE 3 Fosmanogepix USD ~1.0 bn peak sales potential Invasive yeast infections (including Candida auris) Invasive mold infections Ceftibuten-ledaborbactam USD ~500 mn peak sales potential Complicated urinary tract infections (cUTI) PHASE 2 AND EARLIER BAL2062 Invasive aspergillosis BAL2420 (LptA inhibitor) Severe Enterobacteriaceae infections 1The registration status and approved indications may vary from country to country. HABP, CABP: Hospital- and community-acquired bacterial pneumonia, SAB: Staphylococcus aureus bacteremia, ABSSSI: acute bacterial skin and skin structure infections. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Innovative anti-infective pipeline Addressing urgent and evolving infection threats
Page 6
6 Creating anti-infective opportunities Expanding future pipeline opportunities through early- stage collaborations and partnerships Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Phare Bio Artificial intelligence-powered discovery of novel antibacterial agents Prokaryotics Developing novel broad-spectrum antifungal targeting severe invasive infections Provide access to innovative anti-infective technologies and potential future pipeline opportunities
Page 7
7 Creating anti-infective opportunities Adesh Kaul Chief Financial Officer Commercial & Financial Update
Page 8
8 Creating anti-infective opportunities MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026 Cresemba’s in-market sales continue double-digit growth 782 USD million April 2025 to March 2026 27% year-on-year growth Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 100 MAT Q1/2022 MAT Q1/2024 MAT Q1/2024 MAT Q1/2025 MAT Q1/2026 500 400 300 200 600 700 800 900
Page 9
9 Creating anti-infective opportunities Zevtera® US launch – Positioned for future success Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 9 GPO: Group Purchasing Organizations; NTAP: New Technology Add-on Payment Launched in the US in July 2025 through commercial partner Innoviva Specialty Therapeutics − Broad market access established: key GPO listings, J- code, Medicaid/340B and NTAP reimbursement support − Positive early clinical experience reflected in increasing account ordering and repeat ordering trends with encouraging medical community feedback − Expanded commercial infrastructure to increase hospital coverage − Long-term growth opportunity supported by US market exclusivity until April 2034
Page 10
10 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Capital efficiency through non-dilutive R&D funding > 440 by BARDA and CARB - X Committed ~ 165 million in USD, rounding consistently applied million out of which Awarded Non-dilutive funding has a long-term positive effect on value creation and risk mitigation: • Preserving shareholder value: No equity component; no dilution to shareholders • Increasing return-on-investment: Reducing Basilea’s share of investment • Reducing financial risk inherent during development: No repayment required
Page 11
11 Creating anti-infective opportunities Note: Consolidated figures in conformity with US GAAP; rounding applied consistently Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Strong financial results H1 2026 – Significant increase in revenue and profit in CHF million H1 2026 H1 2025 Cresemba and Zevtera related revenue of which royalty income of which milestone and upfront payments Other revenue 92.3 57.8 4.7 26.7 90.5 52.1 6.9 13.5 Total revenue 119.0 104.0 Cost of products sold Operating expenses 15.4 72.0 24.2 55.7 Operating profit 31.6 24.0 Net profit 27.9 15.8 Cash and cash equivalents and restricted cash (as of June 30, 2026/2025) 176.0 132.7
Page 12
12 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Strong cash flows while making significant R&D investments Cash flows from operating activities (in CHF million) Note: Consolidated figures in conformity with US GAAP; rounding applied consistently 62.1 19.0 -63.8 -54.1 -32.0 7.1 14.2 17.9 23.1 74.4 20232022 202120202019 H1 2026H1 2025 / FY 2025 H1 2024 / FY 2024
Page 13
13 Creating anti-infective opportunities 0 50 100 150 200 250 5 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 30.06.202601.01.2022 01.01.2023 01.01.2025 49 75 21 Private loan 2022 convertible bonds 2027 convertible bonds Strengthening the balance sheet through debt reduction CHF 150 million debt reduction between 2022-2026 (nominal value) 221 172 97 76 Note: rounding applied consistently 01.01.2026 71 Convertible bond matures 28th July 2027 in CHF million
Page 14
14 Creating anti-infective opportunities Note: Consistent rounding was applied. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Updated FY 2026 financial guidance – Increase in total revenue driving 40% increase in operating profit in CHF million FY 2026 updated guidance FY 2026 previous guidance FY 2025 actuals Cresemba and Zevtera related revenue ~210 ~200 194.4 of which royalty income ~125 ~120 111.6 Total revenue ~ 15% increase ~ 10% increase 232.4 Research and development expenses ~ 20% increase ~ 20% increase 105.9 Operating profit ~ 40% increase ~ 20% increase 51.5
Page 15
15 Creating anti-infective opportunities ~35 65.0 78.9 96.7 111.6 57.8 24.7 33.5 40.4 32.0 3.9 32.7 37.9 57.8 50.8 29.9 0.0 50.0 100.0 150.0 200.0 2022 2023 2024 2025 H1 2026 2026E 57.8 3.9 29.9 Cresemba and Zevtera related revenue Revenue mix shifting towards higher margin revenues – increasing cash contribution Royalties (guidance) Milestones (guidance) Product revenue (guidance) in CHF million Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution ~50 ~125 Royalties Milestones Product revenue H1 2026 20262025202420232022
Page 16
16 Creating anti-infective opportunities Marc Engelhardt Chief Medical Officer Portfolio Update
Page 17
17 Creating anti-infective opportunities Advancing our phase 3 programs toward approval Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Readout & regulatory process Ceftibuten-ledaborbactam: Phase 3 derisked through well-established study design Global phase 3 program in complicated urinary tract infections1 1 Includes pyelonephritis FAST-IC: Global phase 3 in invasive candidiasis and candidemia FORWARD-IM: Global phase 3 in invasive mold infections Readout and regulatory process Fosmanogepix: Phase 3 derisked through positive real-world data 2024 2025 2026 2027 2028 2029
Page 18
18 Creating anti-infective opportunities Fosmanogepix – Phase 3 program on track with growing real-world experience − Differentiated profile − First-in-class mechanism of action − Broad-spectrum activity against molds and yeasts − Excellent tissue penetration − IV and oral formulations − Phase 3 studies1 on track − Clinical experience through Expanded Access Program2 − For patients with serious and/or life-threatening invasive fungal infections and no other available treatment option − Nearly 600 patients treated across 22 countries − Increasing real-world experience supports development program & future market access Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 1 ClinicalTrials.gov ID: NCT05421858, NCT06925321;2 ClinicalTrials.gov ID: NCT06433128 No. of countries (1) (2) (2) (5) (11) (20) (22) Global Expanded Access Program Status on 01 July 2026
Page 19
19 Creating anti-infective opportunities BAL2420 (LptA inhibitor): phase 1 study progressing First-in-class antibiotic targeting highly resistant Gram-negative bacteria − Phase 1 first-in-human dose escalation study1 initiated in Q1 2026 and progressing as planned − Targeting the most frequent Gram- negative pathogens causing infections (Enterobacteriaceae), including carbapenem-resistant isolates − Novel mechanism targeting LPS transport in Gram-negative bacteria Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 1 ClinicalTrials.gov ID: NCT07500181 BAL2420 destroys the LPS transport bridge The outer cell membrane becomes compromised and LPS accumulate at the inner cell membrane, leading to rapid bacterial cell death.
Page 20
20 Creating anti-infective opportunities Additional pipeline assets supporting future growth Antibacterial and antifungal assets Ceftibuten-ledaborbactam Phase 3 candidate Beta lactam/beta lactamase inhibitor (BL/BLI) 1 QIDP and Fast Track designations by the FDA for cUTI and uncomplicated urinary tract infections. BAL2062 Phase 2 candidate Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − Potential first oral BL/BLI combination for complicated urinary tract infections − Addresses multidrug-resistant Gram- negative infections − FDA Fast Track and QIDP designations1 − Phase 3 preparations progressing for planned start mid-2027 − Novel antifungal for invasive aspergillosis, including resistant strains − New mode of action with potential efficacy advantages − Encouraging phase 1 safety and tolerability profile − Regulatory pathway discussions ongoing
Page 21
21 Creating anti-infective opportunities Chief Executive Officer David Veitch “Agenda 2030” and Summary
Page 22
22 Creating anti-infective opportunities 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Commercial portfolio outlook Targeting four commercial products by 2030 Cresemba Fosmanogepix Ceftibuten-ledaborbactam Ceftibuten- ledaborbactam targeted launch Zevtera US launch Fosmanogepix targeted launch Zevtera
Page 23
23 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution “Agenda 2030” – Delivery on track Strong operational execution reinforces confidence in our financial targets Strong financial position − CHF 160 million cash as of end-2025 − Approx. CHF 600 million cumulative cash flow from Cresemba and Zevtera from 2026 to 2030 − More than USD 350 million potential non-dilutive funding from existing agreements (awarded and potential future tranches) from 2026 to 2030 − Bring phase 3 programs to market with the potential to double current in-market sales − Advance early-stage pipeline − In-license or acquire exciting new assets This allows us to
Page 24
24 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − Cresemba & Zevtera revenue Cresemba global in-market sales continue showing impressive double-digit growth − Phase-3 programs Fosmanogepix two phase 3 studies progressing as planned Preparations on-track for initiating ceftibuten-ledaborbactam phase 3 program mid 2027 − Preclinical and early-stage clinical programs Initiated phase 1 study with novel antibiotic BAL2420 Entered new collaboration for preclinical development − Non-dilutive R&D funding for anti-infectives portfolio Awarded USD 61 million of non-dilutive funding in 2026 for our R&D pipeline programs We continue to deliver on our goals
Page 25
25 Creating anti-infective opportunities Q & A Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 26
26 Creating anti-infective opportunities Capital Markets Day October 28, 2026 Zürich, Switzerland
Page 27
27 Creating anti-infective opportunities Thank you Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 28
28 Creating anti-infective opportunities Glossary − ABSSSI Acute bacterial skin and skin structure infections − BARDA Biomedical Advanced Research and Development Authority − BL/BLI Beta-lactam/Beta-lactamase inhibitor − CABP Community-acquired bacterial pneumonia − CARB-X Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator − CHF Swiss Franc − cUTI Complicated Urinary Tract Infections − EU European Union − FDA US Food and Drug Administration − FY Full Year − HABP Hospital-acquired bacterial pneumonia − GPO Group Purchasing Organizations Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − IV Intravenous − LPS Lipopolysaccharide − LptA Lipopolysaccharide transport protein A − MAT Moving Annual Total − Mn Million − NTAP New Technology Add-On Payment − QIDP Qualified Infectious Disease Product − R&D Research and Development − ROW Rest Of World − SAB Staphylococcus aureus bacteremia − US United States − US GAAP United States Generally Accepted Accounting Principles − USD United States Dollar − Y-o-y year-on-year
Page 29
29 Creating anti-infective opportunities All rights reserved. © Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland info@basilea.com www.basilea.com Shaping the Future of Infectious Diseases